Considerations for post-licensure group B streptococcus vaccine effectiveness studies

Helen Skirrow; Dan Kajungu; Kirsty Le Doare; Tracey Chantler; Beate Kampmann

doi:10.1002/ijgo.14845

Considerations for post-licensure group B streptococcus vaccine effectiveness studies

Int J Gynaecol Obstet. 2023 Jul;162(1):183-185. doi: 10.1002/ijgo.14845. Epub 2023 May 11.

Authors

Helen Skirrow¹, Dan Kajungu^{2

3}, Kirsty Le Doare^{4

5}, Tracey Chantler⁶, Beate Kampmann^{6

7}

Affiliations

¹ Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK.
² Makerere University Centre for Health and Population Research, Iganga, Uganda.
³ Department of Global Health, Stellenbosch University, Stellenbosch, South Africa.
⁴ Centre for Paediatric and Neonatal Infection, St. George's University of London, London, UK.
⁵ Makerere University, John's Hopkins University, Kampala, Uganda.
⁶ The Vaccine Centre, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK.
⁷ Charite Centre for Global Health, Berlin, Germany.

Abstract

Post‐licensure studies of a Group B streptococcal vaccines for pregnant women in low and middle‐income countries will require investment in electronic health records.

Keywords: group B streptococcal disease; pregnancy; vaccines.

MeSH terms

Female
Humans
Pregnancy
Pregnancy Complications, Infectious* / prevention & control
Streptococcal Infections* / prevention & control
Streptococcus agalactiae
Vaccination
Vaccine Efficacy

Abstract

MeSH terms

Grants and funding